文献速递前列腺癌

前列腺癌原发及转移性非去势与去势抵抗状态的基因组特征:183例患者的新一代测序研究

Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-02-27

该研究对183例前列腺癌患者进行新一代测序,包括原发腺癌97例、局部晚期12例、转移性非去势21例和去势抵抗54例。发现TP53改变在高危原发癌中富集,TP53/RB1改变在高级别神经内分泌疾病中富集,AR改变在转移和去势抵抗疾病中富集。约五分之一病例存在可操作改变(MSI-H表型和HRR基因)。

要点

  • TP53改变在高危原发前列腺癌中富集。
  • TP53/RB1改变在高级别神经内分泌疾病中富集。
  • AR改变在转移性和去势抵抗性疾病中富集。

核心结论

  • 这些结果有助于阐明前列腺癌临床谱系中的基因组改变全景。

研究设计与样本

  • 对183例前列腺癌患者的新一代测序结果进行评价,包括原发腺癌97例、局部晚期疾病(累及膀胱/直肠)12例、转移性非去势21例和去势抵抗54例。

主要发现

  • TP53改变在高危原发前列腺癌中富集。
  • TP53/RB1改变在高级别神经内分泌疾病中富集。
  • AR改变在转移性和去势抵抗性疾病中富集。
  • 可操作改变(MSI-H表型和HRR基因)在约五分之一的所有病例中被识别。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment of TP53 alterations in high-grade pPC, TP53/RB1 alterations in HGNE disease, and AR alterations in metastatic and castrate resistant disease. Actionable alterations (MSI-H phenotype and HRR genes) were identified in approximately a fifth of all cases. These results help elucidate the landscape of genomic alterations across the clinical spectrum of prostate cancer.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Dasari S, McCarthy MR, Wojcik AA, et al. Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients. Prostate Cancer Prostatic Dis. 2024. PMID: 38413763. doi:10.1038/s41391-024-00814-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。